De'Oliviera J, Gaskin G, Dash A, Rees A J, Pusey C D
Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.
Am J Kidney Dis. 1995 Mar;25(3):380-9. doi: 10.1016/0272-6386(95)90098-5.
Autoantibodies directed against neutrophil cytoplasmic antigens (ANCA) are valuable in the diagnosis of primary systemic vasculitis, and immunofluorescence studies suggest that changes in ANCA concentration reflect changes in disease activity. We used enzyme-linked immunosorbent assays to examine retrospectively the relationship between ANCA concentration and disease activity in 56 patients with systemic vasculitis. We included patients with Wegener's granulomatosis, microscopic polyangiitis, idiopathic rapidly progressive glomerulonephritis, and Churg-Strauss syndrome, and examined separately the initial treatment period (mean length of follow-up, 26 months) and long-term management (mean length of follow-up, 59 months). Levels of ANCA decreased during induction therapy with prednisolone and cyclophosphamide, with or without plasma exchange. During follow-up, 27 relapses were documented in 20 patients (10 with Wegener's granulomatosis, nine with microscopic polyangiitis, and one with Churg-Strauss syndrome), occurring between 4 and 183 months (mean, 62 months) after initial presentation. Patients in whom ANCA were detectable 1 year or more after treatment were at particular risk of clinical relapse. Proteinase 3-directed ANCA appeared to be associated with a higher rate of relapse (44% of patients relapsed) than myeloperoxidase-directed ANCA (13% of patients relapsed). Twenty-four of the 27 relapses occurred in the presence of detectable ANCA; in 21 of these, ANCA concentration was high or rising. The temporal relationship between changes in ANCA concentration and clinical relapse varied considerably between patients; in seven patients, ANCA remained at high levels for many months (range, 14 to 67 months) before eventual relapse. One patient showed high concentrations of ANCA over a period of 11 years without relapse. In five patients, increases in the ANCA level were not temporally associated with relapse (although four of these patients relapsed on other occasions.) We conclude that monitoring ANCA by enzyme-linked immunosorbent assays is of value in the long-term management of patients with Wegener's granulomatosis, microscopic polyangiitis, idiopathic rapidly progressive glomerulonephritis, and Churg-Strauss syndrome. Increases in ANCA and persistently high levels point to the risk of relapse and indicate the need for frequent clinical review and continuing maintenance immunosuppression. However, our results suggest that ANCA assays should always be used in conjunction with other indices of disease activity and should not be the sole basis for changing therapy.
抗中性粒细胞胞浆抗体(ANCA)在原发性系统性血管炎的诊断中具有重要价值,免疫荧光研究表明,ANCA浓度的变化反映了疾病活动度的变化。我们采用酶联免疫吸附测定法,对56例系统性血管炎患者的ANCA浓度与疾病活动度之间的关系进行了回顾性研究。我们纳入了韦格纳肉芽肿、显微镜下多血管炎、特发性快速进展性肾小球肾炎和变应性肉芽肿性血管炎综合征患者,并分别对初始治疗期(平均随访时间26个月)和长期管理期(平均随访时间59个月)进行了研究。在使用泼尼松龙和环磷酰胺诱导治疗期间,无论是否进行血浆置换,ANCA水平均下降。在随访期间,20例患者(10例韦格纳肉芽肿、9例显微镜下多血管炎和1例变应性肉芽肿性血管炎综合征)出现了27次复发,复发发生在初次就诊后的4至183个月(平均62个月)。治疗后1年或更长时间仍可检测到ANCA的患者临床复发风险尤其高。抗蛋白酶3的ANCA似乎比抗髓过氧化物酶的ANCA复发率更高(44%的患者复发)(13%的患者复发)。27次复发中有24次发生在可检测到ANCA的情况下;其中21次,ANCA浓度高或在升高。ANCA浓度变化与临床复发之间的时间关系在患者之间差异很大;7例患者在最终复发前,ANCA高水平持续了数月(14至67个月)。1例患者11年来ANCA浓度一直很高但未复发。5例患者ANCA水平升高与复发在时间上无关联(尽管其中4例患者在其他时间复发)。我们得出结论,通过酶联免疫吸附测定法监测ANCA,对韦格纳肉芽肿、显微镜下多血管炎、特发性快速进展性肾小球肾炎和变应性肉芽肿性血管炎综合征患者的长期管理具有重要价值。ANCA升高和持续高水平提示复发风险,表明需要频繁进行临床复查并持续进行维持性免疫抑制治疗。然而,我们的结果表明,ANCA检测应始终与其他疾病活动指标结合使用,不应作为改变治疗的唯一依据。